抗血小板膜P2Y12受体拮抗剂的研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (7): 824-830.

抗血小板膜P₂Y₁₂受体拮抗剂的研究进展

张银妆, 陈碧莲

中南大学湘雅医院老年病科,长沙 410078,湖南

收稿日期:2012-12-18 修回日期:2013-06-05 出版日期:2013-07-26 发布日期:2013-06-20
通讯作者: 陈碧莲,女,博士,硕士研究生导师,副主任医师,主要从事心血管疾病研究。Tel: 13975161661 E-mail: bilian18@sina.com.cn
作者简介:张银妆,女,硕士研究生,主要从事心血管疾病研究。E-mail: 804962763@qq.com

Research progress on the platelet P₂Y₁₂ receptor antagonists

ZHANG Yin-zhuang¹, CHEN Bi-lian²

¹Department of Geriatrics, Xiangya Hospital;
²Central South University, Changsha 410078, Hunan, China

Received:2012-12-18 Revised:2013-06-05 Online:2013-07-26 Published:2013-06-20

摘要/Abstract

摘要： 抗血小板药物是治疗急性冠脉综合征的必备用药,其中抗血小板膜P₂Y₁₂受体拮抗剂已成为急性冠脉综合征药物治疗研究中最活跃的一个领域,从基础到临床研究,不断地开发出系列新药。本文就对P₂Y₁₂受体拮抗剂作用机制、药代动力学、急性冠脉综合征临床研究、临床指南等进行分析,为临床合理用药提供参考。

关键词: 抗血小板药物, P₂Y₁₂受体拮抗剂, 急性冠脉综合征

Abstract: Anti-platelet drugs are the essential drugs to treat the acute coronary syndromes. Among them,anti-platelet P₂Y₁₂ receptor antagonists have been the most active studying drugs to treat the patients with acute coronary syndromes. A series of drugs have been developed from basic studies to clinic studies. In this review, we discussed P₂Y₁₂ receptor antagonists including their mechanism of action, pharmacokinetics, clinical researches of the acute coronary syndromes and guidelines for clinical application to provide reference for rational drugs treatment.

Key words: Anti-platelet drug, P₂Y₁₂ receptor antagonists, Acute coronary syndromes

中图分类号:

R969

张银妆, 陈碧莲. 抗血小板膜P₂Y₁₂受体拮抗剂的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(7): 824-830.

ZHANG Yin-zhuang, CHEN Bi-lian. Research progress on the platelet P₂Y₁₂ receptor antagonists[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 824-830.

参考文献

[1] Abbracchio MP, Burnstock G, Boeynaems JM, et al. International Union of Pharmacology LVIII: update on the P₂Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy[J]. Pharmacol Rev, 2006, 58(3): 281-341.
[2] O'Connor S, Montalescot G, Collet JP. The P₂Y receptor as a target of antithrombotic drugs[J]. Purinergic Signal, 2011, 7(3): 325-332.
[3] Knudsen JB, Bastain W, Sefton CM, et al. Pharmacokinetics of ticlopidine during chronic oral administr ation to healthy volunteers and its effects on antipyrine pharmacokinetics[J]. Xenobiot Ica, 1992, 22(5): 579-589.
[4] Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group[J]. N Engl J Med, 1989, 321(8): 501-507.
[5] Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management[J]. Drug Saf, 1998,19(2): 89-98.
[6] Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence[J]. J Am Coll Cardiol, 2005, 45(8): 1157-1164.
[7] Feher G, Feher A, Pusch G, et al. Clinical importance of aspirin and clopidogrel resistance[J]. World J Cardiol, 2010, 2(7): 171-186.
[8] Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001, 345(7): 494-502.
[9] Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial[J]. Lancet, 2005, 366(9497): 1607-1621.
[10] Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and ?brinolytic therapy for myocardial infarction with ST-segment elevation[J]. N Engl J Med, 2005, 352(12):1179-1189.
[11] Mehta SR, Yusuf S, Peter RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet, 2001, 358(9281): 527-533.
[12] Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial[J]. JAMA, 2002, 288(19): 2411-2420.
[13] Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2×2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy[J]. Am Heart J, 2008, 156(6): 1080-1088.
[14] Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists[J]. Br J Clin Pharmacol, 2011,72(4):647-657.
[15] Williams ET, Jones KO, Ponsler GD,et al.The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2[J]. Drug Metab Dispos, 2008, 36(7): 1227-1232.
[16] Damman P, Woudstra P, Kuijt WJ, et al. P₂Y₁₂ platelet inhibition in clinical practice[J]. J Thromb Thrombolysis, 2012, 33(2): 143-153.
[17] Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2007, 357(20): 2001-2015.
[18] John J, Koshy SK. Current oral antiplatelets: focus update on prasugrel[J]. J Am Board Fam Med, 2012, 25(3): 343-349.
[19] Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review[J]. J Blood Med, 2012, 3: 333-342.
[20] James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P₂Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial[J]. Am Heart J, 2009, 157(4): 599-605.
[21] Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI[J]. N Engl J Med, 2009, 361(24): 2330-2341.
[22] Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J, 2005, 26(8): 804-847.
[23] Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases[J]. Br J Pharmacol, 2010, 159(3): 502-517.
[24] 2012 writing committee members. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation. 2012, 126(7): 875-910.
[25] Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2011, 32(23): 2999-3054.
[26] 中国医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2010, 38(8): 675-688.

抗血小板膜P₂Y₁₂受体拮抗剂的研究进展

Research progress on the platelet P₂Y₁₂ receptor antagonists

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[2]	卢希娅, 李玉星, 李文智, 彭园园, 胡宜, 万李, 陈碧莲. 老年医学科冠心病患者抗血小板药物服用情况的调查分析[J]. 中国临床药理学与治疗学, 2022, 27(11): 1285-1291.
[3]	邓毅凡, 何胜虎, 王大新, 戴承晔, 徐笑挺, 张晶. 依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 1048-1052.
[4]	张倩, 付红, 陈瑾瑾, 朱余兵. IL-33/ST2在急性冠脉综合征中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1075-1080.
[5]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.
[6]	章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.
[7]	周碧蓉, 陈越峰, 周娜, 杨景. 急性冠脉综合征患者血清高敏C反应蛋白和组织蛋白酶S水平变化与临床意义[J]. 中国临床药理学与治疗学, 2013, 18(9): 1036-1039.
[8]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.
[9]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J]. 中国临床药理学与治疗学, 2012, 17(9): 1074-1080.
[10]	吴雅凝, 赵娣, 李宁, 陈西敬. 二磷酸腺苷受体拮抗剂类抗血小板药物研究进展[J]. 中国临床药理学与治疗学, 2010, 15(12): 1434-1440.
[11]	柯永胜. 新型抗凝药物直接Xa因子抑制剂利伐沙班[J]. 中国临床药理学与治疗学, 2009, 14(4): 361-367.
[12]	陈碧莲, 解勤之, 李清. 急性冠脉综合征患者氯吡格雷抵抗与近期疗效的临床观察[J]. 中国临床药理学与治疗学, 2009, 14(3): 328-332.
[13]	吴旭斌, 钱宗杰, 伍广伟, 林英忠, 胡昌兴. 罗格列酮对无糖尿病急性冠脉综合征患者外周血单核细胞合成TNF-α和组织因子的影响[J]. 中国临床药理学与治疗学, 2009, 14(2): 180-185.
[14]	吴旭斌, 汤圣兴, 伍广伟, 林英忠, 胡昌兴. 阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响[J]. 中国临床药理学与治疗学, 2009, 14(1): 98-102.
[15]	张品, 何胜虎, 陈述, 张惹, 严风姊, 燕建峰, 赵福全, 徐返华. 曲美他嗦对非ST段抬高急性冠脉综合征患者心肌缺血和心率变异的影响[J]. 中国临床药理学与治疗学, 2007, 12(12): 1432-1435.